Biospecimen Acquisition, Processing and Classification Unit

项目总结（生物标本单元） MSKCC是世界上最大和最繁忙的癌症中心之一， 产生全面的人肿瘤坏死酶。每年，MSKCC看到超过62万 门诊，进行了21，000多例手术，并进行了460，000多例诊断和 介入放射学程序。总的来说，这些资源优势表明我们拥有 患者数量和专业知识，以获得全面分析 从原发性肿瘤到转移的转变。该提案寻求支持， 肺癌、胰腺癌和中枢神经系统转移的综合图谱。这些代表 常见临床场景、关键未满足需求以及MSKCC已经存在的领域 深入和广泛的研究计划。因此，该生物样本单元的目标是获取、注释 并提供高质量的生物标本来支持这三种酶的创建。一是 建立一个前瞻性、高质量的肺手术切除或活检材料生物储存库 癌症、胰腺癌和CNS转移，目的是获得时间信息 关于从原发肿瘤类型到转移的转变。接下来，我们将建立一个高质量的 肺癌、胰腺癌或CNS患者死后衍生组织的生物保藏 通过研究（温暖）尸检程序转移。这种方法将允许收集 关于原发性肿瘤类型向转移的过渡的时间和空间信息， 在同一个人的不同器官部位。最后，我们将优化隔离 单细胞和交叉验证这些方法与合作机构的基础上的理由 单细胞分离的最佳方法可能是组织类型和环境特异性的。最后， 我们的目标是为这些和其他肿瘤类型的合作努力和未来计划的研究提供信息， 通过HTAN。

PROJECT SUMMARY (Biospecimen Unit) MSKCC is one of the largest and busiest cancer centers in the world, ideally positioned to support generation of comprehensive Human Tumor Atlases. On an annual basis MSKCC sees over 620,000 outpatient visits, performs over 21,000 surgeries, and conducts over 460,000 diagnostic and interventional radiology procedures. Collectively, these resource strengths indicate we have the patient volumes and expertise to obtain the samples required for comprehensive profiling of the transition from a primary tumor to metastasis. This proposal seeks support for the generation of comprehensive atlases of Lung Cancer, Pancreatic Cancer, and CNS Metastases. These represent common clinical scenarios, critical unmet needs, and areas in which MSKCC already has existing deep and broad research programs. Thus, the goal of this Biospecimen Unit is to acquire, annotate and supply high quality biospecimens to support creation of these three Atlases. First, we will establish a prospective, high quality biorepository from surgically resected or biopsy materials of lung cancer, pancreatic cancer and CNS metastases with the goal of obtaining temporal information regarding the transition from primary tumor type to metastasis. Next, we will establish a high quality biorepository of postmortem derived tissues of patients with lung cancer, pancreatic cancer or CNS metastasis through a research (warm) autopsy program. This approach will allow collection of both temporal and spatial information regarding the transition from primary tumor type to metastasis in different organ sites in the same individual. Finally, we will optimize methodologies for isolation of single cells and cross validate these methods with collaborating institutions based on the rationale that the optimal methods for single cell isolation are likely tissue-type and context specific. Ultimately, we aim to inform collaborative efforts and future planned studies of these and additional tumor types through the HTAN.